Compare Ishares Msci Brazil ETF (EWZ) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ishares Msci Brazil ETF vs Repligen Corporation Common Stock — how do they compare? Ishares Msci Brazil ETF trades at $42.01 (market cap $13.14B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Ishares Msci Brazil ETF is the larger of the two by market cap, and Ishares Msci Brazil ETF is more actively traded (52,443,793 versus 1,259,263). Which is the better fit depends on your goals — on Pluang, investors hold Ishares Msci Brazil ETF for 50 Days and Repligen Corporation Common Stock for 0 Days on average.
| EWZ | RGEN | |
|---|---|---|
Market Cap | $13.14B | $11.14B |
Volume | 52,443,793 | 1,259,263 |
Sector | Broad Market / Factor | Health |
52-Week High | $43.54 | $194.57 |
52-Week Low | $29.24 | $102.87 |
Typical Hold Time | 50 Days | 0 Days |
Enterprise Value | — | $11.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWZ, the iShares MSCI Brazil ETF, trades at $42.87, down 1.54% today, with a bullish technical signal driven by moving averages but showing overbought RSI levels. The ETF is attracting significant attention due to Brazil's upcoming October election, with institutional investors accumulating positions through call options. Recent news highlights EWZ as a diversification tool against U.S. tech concentration and potential beneficiary of Brazilian economic policies.
The outlook for EWZ hinges on Brazil's political election outcome and commodity trends, offering asymmetric upside but facing currency and political volatility risks. Wall Street positioning suggests optimism, though investors must weigh the ETF's higher expense ratio against alternatives like FLBR for Brazilian exposure.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ishares Msci Brazil ETF
EWZ is a country-specific ETF that tracks the Brazilian equity market. It provides exposure to large and mid-sized companies in Brazil, with a heavy focus on financials and materials, including major names like Nu Holdings, Vale, and Itaú Unibanco.
Read more on EWZ →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
